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CC BY-NC-ND license (http://creativeAbstract Type 2 diabetes mellitus (T2DM) and post-transplant diabetes mellitus (PTDM) share
a common pathophysiology. However, diabetes mellitus is a complex disease, and T2DM and
PTDM have different etiologies. T2DM is a metabolic disorder, characterized by persistent hy-
perglycemia, whereas PTDM is a condition of abnormal glucose tolerance, with variable onset
after organ transplant. The KCNQ1 and KCNJ11 gene encode potassium channels, which
mediate insulin secretion from pancreatic b-cells, and KCN gene mutations are correlated with
the development of diabetes. However, no studies have been carried out to establish an asso-
ciation between KCNQ1 and KCNJ11 gene polymorphisms and T2DM and PTDM. Therefore, our
study was aimed at the identification of the role of KCNQ1 and KCNJ11 gene polymorphisms
associated with T2DM and the risk of developing PTDM in the Asian Indian population. We have
carried out a caseecontrol study including 250 patients with T2DM, 250 control subjects, 42
patients with PTDM and 98 subjects with non-PTDM. PCR-RFLP analysis was carried out
following the isolation of genomic DNA from EDTA-blood samples. The results of the present
study reveal that two single nucleotide polymorphisms (rs2283228 and rs5210, of the KCNQ1
and KCNJ11 genes, respectively) are associated with both T2DM and PTDM. The results of
our study suggest a role of KCNQ1 and KCNJ11 gene variants in the increased risk of T2DM
and PTDM in the Asian Indian population.of Biochemistry, Kasturba Medical College, Manipal University, Manipal, Karnataka, India.
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Type 2 diabetes mellitus (T2DM) and post-transplant dia-
betes mellitus (PTDM), the latter also known as new-onset
diabetes after transplantation (NODAT), are twomajor forms
of multifactorial metabolic disorder. T2DM is a chronic dis-
ease, characterized by insulin resistance and impaired in-
sulin secretion from pancreatic b-cells1; PTDM is similar to
T2DM in this respect. PTDM is not a separate disease on its
own, but a symptom of an underlying metabolic disorder.2
Renal transplant (RT) recipients with PTDM/NODAT exhibit
similar complications to those of T2DM patients in the gen-
eral population, but at an accelerated rate of onset.3 Up
until now, no clear risk factors for PTDM have been estab-
lished. However, the following characteristics that appear to
predispose patients to the development of PTDM have been
identified: age, race, ethnicity, obesity, cadaver-donor kid-
ney transplant, hepatitis C infection, metabolic syndrome,
glucose intolerance, and immunosuppressive agents/
drugs.4,5 Earlier reports have concluded that a family history
of T2DM increases the risk of PTDM up to seven-fold. The use
of immunosuppressive medications, such as calcineurin in-
hibitors (cyclosporin and tacrolimus) and corticosteroids,
plays an important role in the pathogenesis of PTDM.6,7
Several papers have reported that insulin resistance is an
important factor in the pathophysiology of PTDM; a defect
in insulin secretion may also play a role in the development
of the disease.2,3,8 Genome wide association studies
(GWASs) identified several single nucleotide polymorphisms
(SNPs) that are associated with susceptibility to T2DM.9e11
A GWAS has identified a mutation in the potassium
voltage-gated channel, KQT-like subfamily, member 1
(KCNQ1) gene as an important disease-susceptibility factor
associated with the pathogenesis of diabetes in Asian
ethnic groups.12 KCNQ1 is present in adipose tissue and
mediates insulin secretion; the mutation of the KCNQ1 gene
has been shown to be associated with susceptibility to
T2DM13 and to PTDM.11,14 Candidate-gene studies have
provided strong evidence that a common variant of the
potassium inwardly-rectifying channel, subfamily J, mem-
ber 11 (KCNJ11) gene is also associated with T2DM15 and
PTDM.16 The variants of both the KCNQ1 and KCNJ11 genes
are associated with reduced depolarization-evoked insulin
exocytosis. In order to ascertain whether impaired b-cell
function plays an important role in T2DM and PTDM, we
examined the potential effect of these previously associ-
ated KCNQ1 and KCNJ11 variants on the risk of T2DM and
PTDM following RT, in Asian Indian patients.
Materials and methods
Ethical approval
Ethical approval for this study was obtained from the
ethical committee of Kamineni Hospital, Hyderabad, India,and written informed consent was obtained from all the
patients who participated in the study.
Study design
This was a caseecontrol study carried out in the Department
of Genetics and Molecular Medicine, Kamineni Hospital,
Hyderabad, India. The study enrolled 640 Asian Indian sub-
jects, 250 patients with T2DM, 250 healthy controls, and 140
patients who had undergone RT and been administered
calcineurin inhibitors for >3 months. All the RT patients
underwent routine follow up at the Department of
Nephrology, Kamineni Hospital; 42 of these patients devel-
oped PTDM/NODAT later, as diagnosed by the American
Diabetes Association (ADA) criteria17,18 and were included in
the study, whereas the remaining 98 were termed as non-
PTDM patients and were no longer included. All the
healthy controls were selected from the general population
visiting the hospital, based on their having normal blood
glucose levels and being non-obese. The inclusion or
exclusion of T2DM cases, healthy controls, and RT patients
has been described in our previous publication.18,19
Blood test
A total of 5 mL of peripheral blood was collected from the
T2DM patients and healthy controls: 3 mL of the serum
sample was used for biochemical analyses to confirm the
disease diagnosis of T2DM patients, and 2 mL of the EDTA-
blood sample was used for the molecular analysis of all the
subjects who participated in the study. The clinical and
biochemical assessments of T2DM cases and control sub-
jects have been described in our previous studies.19
PCR and RFLP analyses
Genomic DNA was extracted from peripheral leucocytes
using the salting-out technique, routinely used in our lab-
oratory, as previously described.20 The DNA samples were
stored at 80 C until processed. Genotyping for KCNQ1
(rs2283228) and KCNJ11 (rs5210) variants was carried out
via PCR-RFLP in a 25 mL reaction (Bangalore Genei kit;
Bangalore Genei Pvt. Ltd., Bangalore, Karnataka, India),
using an Applied Biosystems thermal cycler machine (Life
Technologies, Carlsbad, CA, USA), and analyzed by agarose
gel electrophoresis. The primers for both the SNPs have
been published.21,22 Primers for PCR analyses were syn-
thesized by Bio Serve Biotechnologies (BioServe Bio-
technologies, Ltd., Hyderabad, India). The PCR procedure
for both SNPs involved DNA denaturation at 95 C for 5 min,
amplification by 35 cycles of 95 C for 30 s, 60 C for 30 s,
72 C for 45 s, and a final extension at 72 C for 5 min. The
restriction enzymes, BsrI (AYCTGGT) and Hpy1888III
(TCCTYGA) (New England BioLabs Inc., Ipswich, MA, USA),
were first tested with bacteriophage l DNA to confirm their
Figure 1 Digested PCR products of KCNQ1 on 3% agarose gel.
278 I.A. Khan et al.specificity. BsrI was used to digest KCNQ1 PCR products and
Hpy1888III was used to digest KCNJ11 PCR products for 4 h
at 37 C in a 20 mL reaction containing 2.5 mL of distilled
water, 10 units of restriction enzyme per 15 mL of PCR
product, and 2 mL of the appropriate restriction enzyme
buffer. The digested PCR products were analyzed by elec-
trophoresis in 3.5% agarose gels containing ethidium bro-
mide (Figs. 1 and 2).Figure 2 Depiction of digestion ofStatistical analysis
Data are expressed as the mean  SD. Statistical analyses
were carried out using the SPSS software, version 21.0, for
Windows (IBM Corp., New York, NY, USA). Allele and geno-
type frequencies were compared between patients and
controls using the c2 test or a two-sided Fisher’s exact test
(p < 0.05 was considered significant). The c2 test was usedKCNJ11 products on 3% agarose.
Gene polymorphisms in diabetes mellitus 279to compare genotype frequencies in T2DM patients vs.
controls, and PTDM patients vs. controls, assuming both
additive and recessive models. The HardyeWeinberg equi-
librium (HWE) was measured using the c2 test for goodness
of fit. A value of p < 0.05 was considered to indicate a
significant disequilibrium.
Results
Characteristics of the T2DM patients
This study comprised two groups, 250 T2DM patients and
250 healthy controls, from the South Indian population
residing in Telangana or Andhra Pradesh; the comparison
between the anthropometric and clinical characteristics of
the study groups is shown in Table 1. The average age of the
T2DM patients was (57.19  8.22) years with a mean body
mass index (BMI) of (27.5  4.1) kg/m2, whereas the
average age of the controls was (53.93  6.32) years with a
mean BMI of (25.8  3.9) kg/m2. There was a significant
difference in the levels of fasting blood sugar, post-lunch
blood sugar, triglycerides, HDL cholesterol, and total
cholesterol between the T2DM patients and controlsTable 1 Quantifiable characteristics of type 2 diabetes mellitu
S. no Characteristics T2DM Cases (n Z
1 Age (Years) 41e82 (57.19  8
2 Males/Females (%) 138 (55.2%)/112
3 BMI (kg/m2) 27.5  4.1
4 T2DM Interval 13.1  6.3
5 FBS (mg/dL) 143.61  55.66
6 PPBG (mg/dL) 201.29  25.25
7 Triglycerides (mg/dL) 156.42  78.97
8 Total Cholesterol (mg/dL) 183.95  51.54
9 HDL-C (mg/dL) 88.72  23.1
10 LDL-C (mg/dL) 38.76  4.4
11 Family History, n (%) 146 (58.4%)
NA: Not analyzed/Not applicable.
Table 2 Clinical characteristics of patients with post-transplan
subjects.
S. no Baseline characteristics PTDM
1 Males/Females 30/12
2 Age: a) Males (Mean  SD) 39.39
b) Females (Mean  SD) 40.01
3 Weight: a) Males (Mean  SD) 62.73
b) Females (Mean  SD) 61.71
4 a) On CsA therapy 22
b) On Tac therapy 20
5 a) CsA Dose (mg) 163.8
b) Tac Dose (mg) 3.15 
6 a) C2 levels (ng/mL) CsA 750 
b) Trough levels (ng/mL) Tac 9.55 
7 a) C2 levels/dose of CsA 5.24 
b) Trough levels/dose of Tac 3.62 
T-test was performed between PTDM and non-PTDM subjects to obta(p < 0.05). Gender, BMI, LDL cholesterol, and family history
were not significantly associated with T2DM (p > 0.05),
although family history was closely associated with T2DM
(58.4%).Characteristics of PTDM study subjects
The clinical characteristics of PTDM patients are given in
Table 2. In this study, 140 RT patients were selected and
categorized as having PTDM or being non-PTDM, based on
biochemical tests; 30% of RT recipients developed PTDM.
We included the 42 patients diagnosed with PTDM in this
study and excluded the 98 non-PTDM as subjects. There
were 30 male subjects and 12 female subjects in the PTDM
patient group; the mean age of the male and female sub-
jects was similar, i.e., (39.39  2.12) years and (40.0
1  11.63) years, respectively. Of the 42 patients with
PTDM, 22 (54%) received cyclosporin treatment, whereas 20
(47.6%) received tacrolimus. When we performed the t-test
between PTDM and non-PTDM subjects, gender, weight,
subjects with cyclosporine drugs (i.e., CsA, Tac) and along
with the dosage were found statistically significant
(p < 0.05).s patients and healthy controls.
250) Healthy Controls (n Z 250) p Value
.22) 41e60 (53.93  6.32) 0.0003
(44.8%) 144 (57.6%)/106(42.4%) 0.3461
25.8  3.9 0.4306
NA NA
93.54  12.13 <0.0001
117.29  19.07 0.0001
138.77  53.69 <0.0001
175.06  33.05 <0.0001
82.61  20.6 Z0.01
35.53  4.1 Z0.2658
138 (55.2%) Z0.3745
t diabetes mellitus and non-post-transplant diabetes mellitus
(n Z 42) Non-PTDM (n Z 98) p Value
75/23 0.001
 12.12 39.55  10.58 0.27
 11.63 39.26  10.87 0.58
 15.81 66.03  12.73 0.08
 16.93 65.49  13.68 0.09
58 0.01
40 0.02
8  57.4 201.29  76.86 0.03
1.24 3.11  1.62 0.05
299.03 1024.8  353.42 0.23
3.38 8.0  3.32 0.86
2.59 5.52  1.97 0.02
1.96 2.98  1.49 0.02
in the p Values.
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The distribution of the genotype frequencies of KCNQ1 and
KCNJ11 variants in case and control subjects is in accor-
dance with the HWE. We have carried out the statistics for
power analysis, and found to be 72%. The genotypic dis-
tribution of KCNQ1 and KCNJ11 variants and their allelic
frequencies in all the patients (T2DM and PTDM) and con-
trols in this study are given in Table 3.Association of the rs2283228 variant with T2DM
and PTDM in the caseecontrol study
In an analysis of the frequency distribution of alleles and
genotypes, the C allele of the rs2283228 polymorphism
showed a strong association with T2DM (AC vs. AA:
OR Z 2.7 [95% CI: 1.4e4.9], p Z 0.0007, and C vs. A:
OR Z 2.4 [95% CI: 1.4e4.1], p Z 0.0005). A significant
difference was observed in the dominant genotype for
T2DM patients vs. controls (AC þ CC vs. AA: ORZ 2.6 [95%
CI: 1.5e4.7], p Z 0.0004). We evaluated the rs2283228
polymorphism in PTDM patients vs. non-PTDM subjects
(n Z 98) that were not used for the T2DM patients. Sig-
nificant differences were observed between the PTDM
patients and non-PTDM subjects (Table 3). There was a
strong association between PTDM and the polymorphism,
which was similar to that between T2DM and the poly-
morphism (AC vs. AA: OR Z 3.0 [95% CI: 1.4e6.4],
p Z 0.003, and C vs. A: OR Z 2.3 [95% CI: 1.2e4.3],
p Z 0.008). In addition, the difference in the dominant
genotype for PTDM patients was significantly different
from that in the controls (AC þ CC vs. AA: OR Z 3.0 [95%
CI: 1.4e6.3], p Z 0.003).Table 3 Genotype and allele distribution of KCNQ1 and KCN









AA 205 (82%) 231 (92.4%) Reference e
AC 41 (16.4%) 17 (6.8%) 2.7(1.4, 4.9) 0
CC 04 (1.6%) 02 (0.8%) 2.2 (0.4, 12.4) 0
AC þ CC 45 (18%) 19 (7.6%) 2.6 (1.5, 4.7) 0
A 451 (90.2%) 479 (95.8%) Reference e









AA 101 (40.4%) 136 (54.4%) Reference e
AG 109 (43.6%) 81 (32.4%) 1.8(1.2, 2.6) 0
GG 40 (16%) 33 (13.2%) 1.6 (0.9, 2.7) 0
AG þ GG 149 (59.6%) 114 (45.6%) 1.7 (1.2, 2.5) 0
A 311 (62.2%) 353 (70.6%) Reference e
G 189 (37.8%) 147 (29.4%) 1.4 (1.1, 1.9) 0
a Crude odds ratio (95% CI).
b Odds ratio (95% CI) Adjusted for Yates correction.Association of the rs5210 variant with T2DM and
PTDM in the caseecontrol study
The frequency distribution of genotypes and alleles of the
rs5210 polymorphism, in T2DM patients vs. controls, was
determined in order to examine their association with
diabetes risk (Table 3). The frequencies of the AA, AG, and
GG genotypes are 40.4%, 43.6%, 16% in T2DM patients and
54.4%, 32.4%, 13.2% in control subjects, respectively. These
results indicate an association between the rs5210 variant
and T2DM risk in the overall analysis (AG vs. AA: OR Z 1.8
[95% CI: 1.2e2.6], p Z 0.002). We observed a significant
difference between the allele frequencies in T2DM patients
and controls (G vs. A: OR Z 1.4 [95% CI: 1.1e1.9],
p Z 0.004).
We also assessed the rs5210 variant in PTDM patients, as
shown in Table 3. The genotype frequencies for AA, AG, and
GG in PTDM patients vs. non-PTDM subjects are 42.8%,
28.6%, and 28.6% vs. 85.7%, 8.2% and 6.1%. The GG geno-
type is more prevalent in PTDM compared to T2DM patients.
There are statistically significant differences between both
the genotypic distribution and the allelic frequency in PTDM
patients and non-PTDM subjects (AG þ GG vs. AA: ORZ 8.0
[95% CI: 3.4e18.4], pZ 0.0001, and G vs. A: ORZ 6.6 [95%
CI: 3.5e12.4], p < 0.0001).Discussion
In this caseecontrol study, we investigated the association
of KCNQ1 (rs2283228) and KCNJ11 (rs5210) gene poly-
morphisms with T2DM and PTDM in Asian Indians. Previous
studies of the association between different KCNQ1 and









20 (47.6%) 72 (73.5%) Reference e
.0007 22 (52.4%) 26 (26.5%) 3.0(1.4, 6.4) 0.003
.33 00 (00)* 00 (00)* 3.5 (0.06, 183.7) 0.50
.0004 22 (52.4%)* 26 (26.5%) 3.0(1.4, 6.3) 0.003
62 (73.8%) 170 (86.7%) Reference e









18 (42.8%) 84 (85.7%) Reference e
.002 12 (28.6%) 08 (8.2%) 7.0 (2.5, 19.5) 0.0001
.06 12 (28.6%) 06 (6.1%) 9.3 (3.0, 28.1) 0.0001
.001 24 (57.2%) 14 (14.3%) 8.0 (3.4, 18.4) 0.0001
48 (57.2%) 176 (89.8%) Reference e
.004 36 (428%) 20 (10.2%) 6.6 (3.5, 12.4) <0.0001
Gene polymorphisms in diabetes mellitus 281populations.21e25 However, there are no previous reports of
studies that have been carried out with these SNPs (i.e.,
rs2283228 in KCNQ1 gene and rs5210 in KCNJ11 gene) in the
Asian Indian population. To the best of our knowledge, only
a few studies have addressed the influence of KCNQ1 and
KCNJ11 polymorphisms on the risk or pathogenesis of T2DM
in Asian Indians.26e28 Additionally, we intended to investi-
gate the association of KCNQ1 (rs2283228) and KCNJ11
(rs5210) gene polymorphisms with both T2DM and PTDM.
The present study is the first to evaluate the distribution of
rs2283228 and rs5210 polymorphisms in Asian Indian pa-
tients with PTDM, and we simultaneously conducted an
evaluation of patients with T2DM from the same popula-
tion; both groups of patients were assessed with healthy
controls for T2DM subjects and non-PTDM for PTDM sub-
jects. The results of the present study reveal that there is
an association between KCNQ1 and KCNJ11 gene poly-
morphisms and both T2DM and PTDM in Asian Indians.
T2DM and PTDM represent different etiologies for the
same complex disease, and several lines of evidence sup-
port the hypothesis that susceptibility to PTDM, like in the
case of T2DM, has a genetic component. Although no sys-
tematic studies have evaluated this hypothesis, family
studies suggest that instances of PTDM aggregate within
families with a history of T2DM.29 PTDM is well defined, as
sustained hyperglycemia developing in any patient with/
without a family history of diabetes before transplantation,
and meets the present diagnostic criteria from the ADA or
WHO.30 Both the diseases (T2DM and PTDM) show a corre-
lation with changes in the KCNQ1 and KCNJ11 genes. These
genes are located on chromosome 11p13ep12 and 11p15.1.
The KCNQ1 gene encodes the pore-forming subunit of a
voltage-gated potassium channel that plays a key role in
the repolarization of the cardiac-action potential as well as
in the transport of water and salts in epithelial tissues.31
KCNQ1 is expressed in pancreatic b-cells, and KCNJ11
plays a strategic role in insulin secretion by glucose-
stimulated pancreatic b-cells.
A meta-analysis study by Liu et al31 demonstrated a
positive association between the KCNQ1 rs2283228 poly-
morphism and T2DM. The rs2283228 variant, previously
associated with T2DM in European (Danish), but not in
Chinese (Singaporean) and Arab (Tunisian) pop-
ulations,21,32,33 was associated with T2DM in Asian Indians.
The susceptibility-conferring C allele of the rs2283228
variant was associated with increased fasting glucose levels
and impaired b-cell function in Asians.34 Previous studies
from the Caucasian and Korean populations, has identified
the positive association of the KCNQ1 gene with PTDM11,14;
the same positive association was observed with PTDM in
Asian Indian transplant recipients in the present study.
Five studies have investigated the association between
the rs5210 polymorphism in the KCNJ11 gene and T2DM;
these studies included meta-analyses that found this asso-
ciation to be significantly heterogeneous (p Z 0.02).35 The
rs5210 polymorphism has been shown to be associated with
T2DM in Finnish, Korean, and Mexican populations,22,36,37
and our results in Asian Indian T2DM patients are consis-
tent with the results of these studies. There have been two
studies carried out in PTDM patients in relation to the
KCNJ11 gene, i.e., Tavira et al16 reported that PTDM was
associated with the rs5219 polymorphism in the CaucasianSpanish population, and Kurzawski et al38 carried out an
assessment of the rs5215 polymorphism in the Caucasian
Polish population and reported that it was not associated
with PTDM. Our study was carried out in the Asian Indian
population, and we identified that the rs5210 polymorphism
was associated with PDTM in a similar way as it was asso-
ciated with T2DM.
Limitations of the current study include the small num-
ber of patients confirmed with PTDM (n Z 42) and our se-
lection of only one SNP from each gene. We had missed out
the glucose values for PTDM and non-PTDM subjects, which
could be another limitation of our study. We also did not
consider the interactions between the gene and its protein,
which could require further studies. We have conducted the
present study with single SNPs of the KCNQ1 and KCNJ11
genes and found these to be associated with both T2DM and
PTDM in Asian Indian patients.
Conclusion
In conclusion, we conclude that there is a significant asso-
ciation between the KCNQ1 and KCNJ11 genes and the risk
of developing T2DM and PTDM in Asian Indians. Further
studies are needed to confirm these findings in different
ethnicities, together with functional studies.
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